Cargando…

Validity of the SARC-F questionnaire in assessing sarcopenia in patients with chronic kidney disease: a cross-sectional study

OBJECTIVE: To examine the validity of the 5-component SARC-F questionnaire for screening sarcopenia among patients with chronic kidney disease (CKD). METHODS: Eligible participants were enrolled from the Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine from...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Wen, Gao, Chenni, Wang, Xuejie, Ma, Xiaobo, Xie, Jingyuan, Yu, Haijin, Yang, Zhenhua, Chen, Zijin, Chen, Xiaonong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391647/
https://www.ncbi.nlm.nih.gov/pubmed/37534318
http://dx.doi.org/10.3389/fmed.2023.1188971
_version_ 1785082757886509056
author Du, Wen
Gao, Chenni
Wang, Xuejie
Ma, Xiaobo
Xie, Jingyuan
Yu, Haijin
Yang, Zhenhua
Chen, Zijin
Chen, Xiaonong
author_facet Du, Wen
Gao, Chenni
Wang, Xuejie
Ma, Xiaobo
Xie, Jingyuan
Yu, Haijin
Yang, Zhenhua
Chen, Zijin
Chen, Xiaonong
author_sort Du, Wen
collection PubMed
description OBJECTIVE: To examine the validity of the 5-component SARC-F questionnaire for screening sarcopenia among patients with chronic kidney disease (CKD). METHODS: Eligible participants were enrolled from the Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine from March 2019 to November 2019. Evaluations were performed using the self-administered SARC-F questionnaire. Sarcopenia was diagnosed by grip strength, the chair stand test and appendicular skeletal muscle mass. The severity of sarcopenia was evaluated by gait speed. We calculated the sensitivity and specificity of the SARC-F to evaluate construct validity. Moreover, receiver operating characteristic (ROC) curve analysis was performed to identify the cutoff value for nondialysis-dependent (NDD) CKD patients’ and maintenance hemodialysis (MHD) patients’ scores. RESULTS: A total of 105 NDD-CKD patients and 125 MHD patients were included, and the prevalence of sarcopenia was 5.7 and 31.2%, respectively. Among them, there were 21 (16.8%) MHD patients with severe sarcopenia but no NDD-CKD patients with severe sarcopenia. The sensitivity and specificity of the SARC-F were 16.7 and 98.0% for NDD-CKD patients, and 48.7 and 89.5% for MHD patients, respectively. For NDD-CKD patients, the area under the receiver operating characteristic curve (AUROC) of the total SARC-F score was 0.978 (95% confidence interval (CI): 0.929–0.997, p < 0.001), and the cutoff value of 1 reached the highest Youden index of 0.950 and max ROC curve area of 0.974. For MHD patients, the AUROC of the total SARC-F score was 0.730 (95% CI: 0.644–0.806, p < 0.001), and the cutoff value of 4 reached the highest Youden index of 0.383 and max ROC curve area of 0.691. CONCLUSION: CKD patients, especially MHD patients, were at high risk of suffering sarcopenia. The SARC-F had low-to-moderate sensitivity but high specificity for screening sarcopenia among patients with CKD. The best cutoff values of the SARC-F score were different for screening sarcopenia among NDD-CKD and MHD patients.
format Online
Article
Text
id pubmed-10391647
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103916472023-08-02 Validity of the SARC-F questionnaire in assessing sarcopenia in patients with chronic kidney disease: a cross-sectional study Du, Wen Gao, Chenni Wang, Xuejie Ma, Xiaobo Xie, Jingyuan Yu, Haijin Yang, Zhenhua Chen, Zijin Chen, Xiaonong Front Med (Lausanne) Medicine OBJECTIVE: To examine the validity of the 5-component SARC-F questionnaire for screening sarcopenia among patients with chronic kidney disease (CKD). METHODS: Eligible participants were enrolled from the Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine from March 2019 to November 2019. Evaluations were performed using the self-administered SARC-F questionnaire. Sarcopenia was diagnosed by grip strength, the chair stand test and appendicular skeletal muscle mass. The severity of sarcopenia was evaluated by gait speed. We calculated the sensitivity and specificity of the SARC-F to evaluate construct validity. Moreover, receiver operating characteristic (ROC) curve analysis was performed to identify the cutoff value for nondialysis-dependent (NDD) CKD patients’ and maintenance hemodialysis (MHD) patients’ scores. RESULTS: A total of 105 NDD-CKD patients and 125 MHD patients were included, and the prevalence of sarcopenia was 5.7 and 31.2%, respectively. Among them, there were 21 (16.8%) MHD patients with severe sarcopenia but no NDD-CKD patients with severe sarcopenia. The sensitivity and specificity of the SARC-F were 16.7 and 98.0% for NDD-CKD patients, and 48.7 and 89.5% for MHD patients, respectively. For NDD-CKD patients, the area under the receiver operating characteristic curve (AUROC) of the total SARC-F score was 0.978 (95% confidence interval (CI): 0.929–0.997, p < 0.001), and the cutoff value of 1 reached the highest Youden index of 0.950 and max ROC curve area of 0.974. For MHD patients, the AUROC of the total SARC-F score was 0.730 (95% CI: 0.644–0.806, p < 0.001), and the cutoff value of 4 reached the highest Youden index of 0.383 and max ROC curve area of 0.691. CONCLUSION: CKD patients, especially MHD patients, were at high risk of suffering sarcopenia. The SARC-F had low-to-moderate sensitivity but high specificity for screening sarcopenia among patients with CKD. The best cutoff values of the SARC-F score were different for screening sarcopenia among NDD-CKD and MHD patients. Frontiers Media S.A. 2023-07-18 /pmc/articles/PMC10391647/ /pubmed/37534318 http://dx.doi.org/10.3389/fmed.2023.1188971 Text en Copyright © 2023 Du, Gao, Wang, Ma, Xie, Yu, Yang,Chen and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Du, Wen
Gao, Chenni
Wang, Xuejie
Ma, Xiaobo
Xie, Jingyuan
Yu, Haijin
Yang, Zhenhua
Chen, Zijin
Chen, Xiaonong
Validity of the SARC-F questionnaire in assessing sarcopenia in patients with chronic kidney disease: a cross-sectional study
title Validity of the SARC-F questionnaire in assessing sarcopenia in patients with chronic kidney disease: a cross-sectional study
title_full Validity of the SARC-F questionnaire in assessing sarcopenia in patients with chronic kidney disease: a cross-sectional study
title_fullStr Validity of the SARC-F questionnaire in assessing sarcopenia in patients with chronic kidney disease: a cross-sectional study
title_full_unstemmed Validity of the SARC-F questionnaire in assessing sarcopenia in patients with chronic kidney disease: a cross-sectional study
title_short Validity of the SARC-F questionnaire in assessing sarcopenia in patients with chronic kidney disease: a cross-sectional study
title_sort validity of the sarc-f questionnaire in assessing sarcopenia in patients with chronic kidney disease: a cross-sectional study
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391647/
https://www.ncbi.nlm.nih.gov/pubmed/37534318
http://dx.doi.org/10.3389/fmed.2023.1188971
work_keys_str_mv AT duwen validityofthesarcfquestionnaireinassessingsarcopeniainpatientswithchronickidneydiseaseacrosssectionalstudy
AT gaochenni validityofthesarcfquestionnaireinassessingsarcopeniainpatientswithchronickidneydiseaseacrosssectionalstudy
AT wangxuejie validityofthesarcfquestionnaireinassessingsarcopeniainpatientswithchronickidneydiseaseacrosssectionalstudy
AT maxiaobo validityofthesarcfquestionnaireinassessingsarcopeniainpatientswithchronickidneydiseaseacrosssectionalstudy
AT xiejingyuan validityofthesarcfquestionnaireinassessingsarcopeniainpatientswithchronickidneydiseaseacrosssectionalstudy
AT yuhaijin validityofthesarcfquestionnaireinassessingsarcopeniainpatientswithchronickidneydiseaseacrosssectionalstudy
AT yangzhenhua validityofthesarcfquestionnaireinassessingsarcopeniainpatientswithchronickidneydiseaseacrosssectionalstudy
AT chenzijin validityofthesarcfquestionnaireinassessingsarcopeniainpatientswithchronickidneydiseaseacrosssectionalstudy
AT chenxiaonong validityofthesarcfquestionnaireinassessingsarcopeniainpatientswithchronickidneydiseaseacrosssectionalstudy